The COVID-19 pandemic accelerated adoption of an array of disruptive development applied sciences, together with e-commerce, fintech, and extra.
Healthcare innovation is a part of that development, and the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is an alternate traded fund for buyers to contemplate because the pandemic compels healthcare professionals to discover new ideas in genetic testing.
Previous to the pandemic, many sufferers did not talk about genetics with main care suppliers, however that panorama is altering.
“Propelled by the COVID-19 pandemic, we consider progressive digital healthcare and genetic testing corporations are poised to deal with these obstacles,” in keeping with ARK Make investments analysis. “Maybe extra importantly, these teams are extremely incentivized to work collectively.”
ARKG’s Genetics Testing Alternatives
On the subject of making genetics testing extra accessible on the main care supplier degree, some ARKG parts are already making the required investments.
“Teams like Teladoc (TDOC), One Medical (ONEM), and Accolade (ACCD) have invested aggressively in digital main care companies. One Medical’s ‘click-and-mortar’ platform spans each digital and in-person main care and incorporates its personal EHR system,” notes ARK Make investments.
Teladoc is ARKG’s largest holding at simply over 7% of the fund’s weight, as of June 1. Accolade and One Medical mix for 3.3% of the fund’s roster.
There are different avenues into the genetics testing realms. For instance, some ARKG member corporations are utilizing AI to boost genetics testing procedures and produce that idea to a wider viewers of sufferers.
“In the meantime, testing suppliers like Natera (NTRA), Invitae (NVTA), and Myriad Genetics (MYGN) have launched AI-enabled chatbots to facilitate genetic testing,” provides ARK. “With acquisitions of Clear Genetics and YouScript, for instance, Invitae’s platform gives consent, pre- and post-test training, automated household historical past assortment, outcomes reporting, digital genetic counseling, integration with digital healthcare data like Epic and Cerner, CDST capabilities, and low-cost patient-pay choices.”
Invitae accounts for 1.76% of ARKG’s weight. The general genetics testing market is forecast to achieve $21.26 billion by 2027, posting a compound annual development fee of 10.1% from 2020 by 2027, in keeping with Allied Market Analysis. Prenatal and predictive and pre-symptomatic testing are the most important segments on this enviornment.
For extra on disruptive applied sciences, go to our Disruptive Know-how Channel.
Learn extra on ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.